Lupus & antiphospholipid syndrome
Measuring the Impact of MyLupusGuide in Canada: Results of a Randomized Controlled Study
Authors' conclusion
MyLupusGuide increases self-efficacy but not patient activation.
Study context
- Population
- People with systemic lupus erythematosus (SLE) (mean ± SE age 50 ± 14 years; 93% female; 74% White; mean ± SE disease duration 17 ± 12 years), Canada56% visited MyLupusGuide at least once
- Participants
- 541 people
- Comparison
- Immediate vs delayed (from month 3) access to the web-based self-management program MyLupusGuide
- Primary endpoint
- Patient activation measure (PAM) score
- Follow-up
- 3 months
Methodological detailsonline, delayed-access control
- Online
- Delayed-access control
Primary result
As reported in the abstract
PAM score
- No differences in patient activation measure (PAM) scores between groups
Secondary outcomes
PAM score in those with low baseline PAM and in male individuals (exploratory subgroups)
- Significant improvement in PAM scores
- Exploratory analyses
Self-efficacy
- Significant improvements before vs after access to MyLupusGuide
Mental health and emotional coping · month 6 vs month 3
- Delayed improvements at month 6 compared to month 3
Original publication
Measuring the Impact of MyLupusGuide in Canada: Results of a Randomized Controlled Study. Arthritis Care Res (Hoboken). Published 17 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →